WO2006103685A2 - A method for cultivating cells derived from corneal limbal tissue and cells deived from corneal limbal tissue - Google Patents
A method for cultivating cells derived from corneal limbal tissue and cells deived from corneal limbal tissue Download PDFInfo
- Publication number
- WO2006103685A2 WO2006103685A2 PCT/IN2005/000092 IN2005000092W WO2006103685A2 WO 2006103685 A2 WO2006103685 A2 WO 2006103685A2 IN 2005000092 W IN2005000092 W IN 2005000092W WO 2006103685 A2 WO2006103685 A2 WO 2006103685A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- gel
- corneal limbal
- tissue
- hydrogel
- cells
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 38
- 239000000499 gel Substances 0.000 claims abstract description 219
- 210000004027 cell Anatomy 0.000 claims abstract description 147
- 229920000642 polymer Polymers 0.000 claims abstract description 113
- 239000000017 hydrogel Substances 0.000 claims abstract description 86
- 230000007704 transition Effects 0.000 claims abstract description 80
- 210000000130 stem cell Anatomy 0.000 claims abstract description 51
- 239000007864 aqueous solution Substances 0.000 claims abstract description 49
- 238000001816 cooling Methods 0.000 claims abstract description 13
- 238000010438 heat treatment Methods 0.000 claims abstract description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 63
- 102100027881 Tumor protein 63 Human genes 0.000 claims description 21
- 210000002919 epithelial cell Anatomy 0.000 claims description 21
- 102000001045 Connexin 43 Human genes 0.000 claims description 19
- 108010069241 Connexin 43 Proteins 0.000 claims description 19
- 238000012744 immunostaining Methods 0.000 claims description 16
- 102000006495 integrins Human genes 0.000 claims description 15
- 108010044426 integrins Proteins 0.000 claims description 15
- 230000001052 transient effect Effects 0.000 claims description 12
- 238000004132 cross linking Methods 0.000 claims description 6
- 238000001711 protein immunostaining Methods 0.000 claims description 3
- 102000013013 Member 2 Subfamily G ATP Binding Cassette Transporter Human genes 0.000 claims 1
- 108010090306 Member 2 Subfamily G ATP Binding Cassette Transporter Proteins 0.000 claims 1
- 238000012364 cultivation method Methods 0.000 claims 1
- 210000004087 cornea Anatomy 0.000 abstract description 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 7
- 201000010099 disease Diseases 0.000 abstract description 6
- 210000001519 tissue Anatomy 0.000 description 164
- 239000000243 solution Substances 0.000 description 65
- 239000002609 medium Substances 0.000 description 60
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 40
- 239000012091 fetal bovine serum Substances 0.000 description 40
- 239000000126 substance Substances 0.000 description 33
- 210000001691 amnion Anatomy 0.000 description 31
- 210000002950 fibroblast Anatomy 0.000 description 30
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 28
- 230000012010 growth Effects 0.000 description 24
- 230000002209 hydrophobic effect Effects 0.000 description 24
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 22
- 239000012153 distilled water Substances 0.000 description 21
- 239000000047 product Substances 0.000 description 21
- 238000000108 ultra-filtration Methods 0.000 description 21
- 239000008279 sol Substances 0.000 description 20
- 230000001413 cellular effect Effects 0.000 description 19
- 238000009792 diffusion process Methods 0.000 description 19
- 239000000178 monomer Substances 0.000 description 19
- ROOXNKNUYICQNP-UHFFFAOYSA-N ammonium persulfate Chemical compound [NH4+].[NH4+].[O-]S(=O)(=O)OOS([O-])(=O)=O ROOXNKNUYICQNP-UHFFFAOYSA-N 0.000 description 18
- 230000010261 cell growth Effects 0.000 description 18
- 238000005259 measurement Methods 0.000 description 16
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 14
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 14
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 14
- 229940104230 thymidine Drugs 0.000 description 14
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 13
- -1 acryl Chemical group 0.000 description 13
- 238000012258 culturing Methods 0.000 description 13
- 229920001451 polypropylene glycol Polymers 0.000 description 13
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 12
- 210000000056 organ Anatomy 0.000 description 12
- 102000008186 Collagen Human genes 0.000 description 11
- 108010035532 Collagen Proteins 0.000 description 11
- 229920001436 collagen Polymers 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 239000000463 material Substances 0.000 description 11
- 239000012528 membrane Substances 0.000 description 11
- 238000006116 polymerization reaction Methods 0.000 description 11
- SOGAXMICEFXMKE-UHFFFAOYSA-N Butylmethacrylate Chemical compound CCCCOC(=O)C(C)=C SOGAXMICEFXMKE-UHFFFAOYSA-N 0.000 description 10
- 239000007788 liquid Substances 0.000 description 10
- 238000004519 manufacturing process Methods 0.000 description 10
- 238000002135 phase contrast microscopy Methods 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 9
- 102000003992 Peroxidases Human genes 0.000 description 9
- 229910001870 ammonium persulfate Inorganic materials 0.000 description 9
- 230000000052 comparative effect Effects 0.000 description 9
- 238000010348 incorporation Methods 0.000 description 9
- 239000012188 paraffin wax Substances 0.000 description 9
- 108040007629 peroxidase activity proteins Proteins 0.000 description 9
- 239000000523 sample Substances 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- 230000003247 decreasing effect Effects 0.000 description 8
- 238000010790 dilution Methods 0.000 description 8
- 239000012895 dilution Substances 0.000 description 8
- 239000003102 growth factor Substances 0.000 description 8
- 229920001992 poloxamer 407 Polymers 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 239000011369 resultant mixture Substances 0.000 description 8
- 238000010186 staining Methods 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 7
- 229910052757 nitrogen Inorganic materials 0.000 description 7
- 239000011541 reaction mixture Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 6
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 6
- 210000001232 limbus corneae Anatomy 0.000 description 6
- QNILTEGFHQSKFF-UHFFFAOYSA-N n-propan-2-ylprop-2-enamide Chemical compound CC(C)NC(=O)C=C QNILTEGFHQSKFF-UHFFFAOYSA-N 0.000 description 6
- 239000002243 precursor Substances 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 238000002054 transplantation Methods 0.000 description 6
- 229920001400 block copolymer Polymers 0.000 description 5
- 210000000845 cartilage Anatomy 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 239000000512 collagen gel Substances 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 125000000524 functional group Chemical group 0.000 description 5
- 230000003450 growing effect Effects 0.000 description 5
- 238000003125 immunofluorescent labeling Methods 0.000 description 5
- 239000010410 layer Substances 0.000 description 5
- 230000033001 locomotion Effects 0.000 description 5
- 230000005012 migration Effects 0.000 description 5
- 238000013508 migration Methods 0.000 description 5
- 230000005855 radiation Effects 0.000 description 5
- 230000000717 retained effect Effects 0.000 description 5
- 230000001954 sterilising effect Effects 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 230000036760 body temperature Effects 0.000 description 4
- 229920001577 copolymer Polymers 0.000 description 4
- 230000004069 differentiation Effects 0.000 description 4
- 239000006185 dispersion Substances 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- 210000001508 eye Anatomy 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 230000001575 pathological effect Effects 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 239000002356 single layer Substances 0.000 description 4
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 4
- 230000004304 visual acuity Effects 0.000 description 4
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2,2'-azo-bis-isobutyronitrile Substances N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 102000010970 Connexin Human genes 0.000 description 3
- 108050001175 Connexin Proteins 0.000 description 3
- 230000006820 DNA synthesis Effects 0.000 description 3
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 3
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 3
- 210000005252 bulbus oculi Anatomy 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000007334 copolymerization reaction Methods 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000008034 disappearance Effects 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 3
- STVZJERGLQHEKB-UHFFFAOYSA-N ethylene glycol dimethacrylate Chemical compound CC(=C)C(=O)OCCOC(=O)C(C)=C STVZJERGLQHEKB-UHFFFAOYSA-N 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000005499 meniscus Effects 0.000 description 3
- 229920000609 methyl cellulose Polymers 0.000 description 3
- 239000001923 methylcellulose Substances 0.000 description 3
- 235000010981 methylcellulose Nutrition 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000008929 regeneration Effects 0.000 description 3
- 238000011069 regeneration method Methods 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 239000012488 sample solution Substances 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 229910052722 tritium Inorganic materials 0.000 description 3
- SJIXRGNQPBQWMK-UHFFFAOYSA-N 2-(diethylamino)ethyl 2-methylprop-2-enoate Chemical compound CCN(CC)CCOC(=O)C(C)=C SJIXRGNQPBQWMK-UHFFFAOYSA-N 0.000 description 2
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 2
- 239000000275 Adrenocorticotropic Hormone Substances 0.000 description 2
- 101800000414 Corticotropin Proteins 0.000 description 2
- 102400000739 Corticotropin Human genes 0.000 description 2
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 2
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 102000012334 Integrin beta4 Human genes 0.000 description 2
- 108010022238 Integrin beta4 Proteins 0.000 description 2
- 102100030856 Myoglobin Human genes 0.000 description 2
- 108010062374 Myoglobin Proteins 0.000 description 2
- 102000003982 Parathyroid hormone Human genes 0.000 description 2
- 108090000445 Parathyroid hormone Proteins 0.000 description 2
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 2
- 229920000954 Polyglycolide Polymers 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 102000011923 Thyrotropin Human genes 0.000 description 2
- 108010061174 Thyrotropin Proteins 0.000 description 2
- XSTXAVWGXDQKEL-UHFFFAOYSA-N Trichloroethylene Chemical compound ClC=C(Cl)Cl XSTXAVWGXDQKEL-UHFFFAOYSA-N 0.000 description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 125000003647 acryloyl group Chemical group O=C([*])C([H])=C([H])[H] 0.000 description 2
- 238000005273 aeration Methods 0.000 description 2
- 150000003862 amino acid derivatives Chemical class 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 2
- 229960000258 corticotropin Drugs 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000003560 epithelium corneal Anatomy 0.000 description 2
- 229940126864 fibroblast growth factor Drugs 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 229920001477 hydrophilic polymer Polymers 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- MCPLVIGCWWTHFH-UHFFFAOYSA-L methyl blue Chemical compound [Na+].[Na+].C1=CC(S(=O)(=O)[O-])=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[NH+]C=2C=CC(=CC=2)S([O-])(=O)=O)C=2C=CC(NC=3C=CC(=CC=3)S([O-])(=O)=O)=CC=2)C=C1 MCPLVIGCWWTHFH-UHFFFAOYSA-L 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000004264 monolayer culture Methods 0.000 description 2
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 2
- YPHQUSNPXDGUHL-UHFFFAOYSA-N n-methylprop-2-enamide Chemical compound CNC(=O)C=C YPHQUSNPXDGUHL-UHFFFAOYSA-N 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- 239000000199 parathyroid hormone Substances 0.000 description 2
- 229960001319 parathyroid hormone Drugs 0.000 description 2
- 239000012466 permeate Substances 0.000 description 2
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920000747 poly(lactic acid) Polymers 0.000 description 2
- 239000004633 polyglycolic acid Substances 0.000 description 2
- 239000004626 polylactic acid Substances 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000001172 regenerating effect Effects 0.000 description 2
- 238000007873 sieving Methods 0.000 description 2
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical compound O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000001291 vacuum drying Methods 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- 229920002818 (Hydroxyethyl)methacrylate Polymers 0.000 description 1
- RESPXSHDJQUNTN-UHFFFAOYSA-N 1-piperidin-1-ylprop-2-en-1-one Chemical compound C=CC(=O)N1CCCCC1 RESPXSHDJQUNTN-UHFFFAOYSA-N 0.000 description 1
- WLPAQAXAZQUXBG-UHFFFAOYSA-N 1-pyrrolidin-1-ylprop-2-en-1-one Chemical compound C=CC(=O)N1CCCC1 WLPAQAXAZQUXBG-UHFFFAOYSA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- JKNCOURZONDCGV-UHFFFAOYSA-N 2-(dimethylamino)ethyl 2-methylprop-2-enoate Chemical compound CN(C)CCOC(=O)C(C)=C JKNCOURZONDCGV-UHFFFAOYSA-N 0.000 description 1
- YJLUBHOZZTYQIP-UHFFFAOYSA-N 2-[5-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-1,3,4-oxadiazol-2-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1=NN=C(O1)CC(=O)N1CC2=C(CC1)NN=N2 YJLUBHOZZTYQIP-UHFFFAOYSA-N 0.000 description 1
- OMIGHNLMNHATMP-UHFFFAOYSA-N 2-hydroxyethyl prop-2-enoate Chemical compound OCCOC(=O)C=C OMIGHNLMNHATMP-UHFFFAOYSA-N 0.000 description 1
- YQIGLEFUZMIVHU-UHFFFAOYSA-N 2-methyl-n-propan-2-ylprop-2-enamide Chemical compound CC(C)NC(=O)C(C)=C YQIGLEFUZMIVHU-UHFFFAOYSA-N 0.000 description 1
- CCIDRBFZPRURMU-UHFFFAOYSA-N 2-methyl-n-propylprop-2-enamide Chemical compound CCCNC(=O)C(C)=C CCIDRBFZPRURMU-UHFFFAOYSA-N 0.000 description 1
- AGBXYHCHUYARJY-UHFFFAOYSA-N 2-phenylethenesulfonic acid Chemical compound OS(=O)(=O)C=CC1=CC=CC=C1 AGBXYHCHUYARJY-UHFFFAOYSA-N 0.000 description 1
- KGIGUEBEKRSTEW-UHFFFAOYSA-N 2-vinylpyridine Chemical compound C=CC1=CC=CC=N1 KGIGUEBEKRSTEW-UHFFFAOYSA-N 0.000 description 1
- CONKBQPVFMXDOV-QHCPKHFHSA-N 6-[(5S)-5-[[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]methyl]-2-oxo-1,3-oxazolidin-3-yl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C[C@H]1CN(C(O1)=O)C1=CC2=C(NC(O2)=O)C=C1 CONKBQPVFMXDOV-QHCPKHFHSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 208000009043 Chemical Burns Diseases 0.000 description 1
- 208000018380 Chemical injury Diseases 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 206010048832 Colon adenoma Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 239000005057 Hexamethylene diisocyanate Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- URLZCHNOLZSCCA-VABKMULXSA-N Leu-enkephalin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 URLZCHNOLZSCCA-VABKMULXSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000721454 Pemphigus Species 0.000 description 1
- 229920002845 Poly(methacrylic acid) Polymers 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- 102000005157 Somatostatin Human genes 0.000 description 1
- 108010056088 Somatostatin Proteins 0.000 description 1
- 102100038803 Somatotropin Human genes 0.000 description 1
- 206010042033 Stevens-Johnson syndrome Diseases 0.000 description 1
- 231100000168 Stevens-Johnson syndrome Toxicity 0.000 description 1
- 102000019259 Succinate Dehydrogenase Human genes 0.000 description 1
- 108010012901 Succinate Dehydrogenase Proteins 0.000 description 1
- 102400000336 Thyrotropin-releasing hormone Human genes 0.000 description 1
- 101800004623 Thyrotropin-releasing hormone Proteins 0.000 description 1
- 102000000591 Tight Junction Proteins Human genes 0.000 description 1
- 108010002321 Tight Junction Proteins Proteins 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- ZJCCRDAZUWHFQH-UHFFFAOYSA-N Trimethylolpropane Chemical compound CCC(CO)(CO)CO ZJCCRDAZUWHFQH-UHFFFAOYSA-N 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 206010064996 Ulcerative keratitis Diseases 0.000 description 1
- GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 1
- 108010004977 Vasopressins Proteins 0.000 description 1
- 102000002852 Vasopressins Human genes 0.000 description 1
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 1
- BZHJMEDXRYGGRV-UHFFFAOYSA-N Vinyl chloride Chemical compound ClC=C BZHJMEDXRYGGRV-UHFFFAOYSA-N 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000007259 addition reaction Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000019552 anatomical structure morphogenesis Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940053200 antiepileptics fatty acid derivative Drugs 0.000 description 1
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 1
- 230000008952 bacterial invasion Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 210000003321 cartilage cell Anatomy 0.000 description 1
- 238000010538 cationic polymerization reaction Methods 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 230000035605 chemotaxis Effects 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000013066 combination product Substances 0.000 description 1
- 229940127555 combination product Drugs 0.000 description 1
- 201000007717 corneal ulcer Diseases 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000005489 elastic deformation Effects 0.000 description 1
- 210000003890 endocrine cell Anatomy 0.000 description 1
- 230000008472 epithelial growth Effects 0.000 description 1
- 210000005081 epithelial layer Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 125000001033 ether group Chemical group 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012847 fine chemical Substances 0.000 description 1
- 210000003976 gap junction Anatomy 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- VOZRXNHHFUQHIL-UHFFFAOYSA-N glycidyl methacrylate Chemical compound CC(=C)C(=O)OCC1CO1 VOZRXNHHFUQHIL-UHFFFAOYSA-N 0.000 description 1
- 229920000578 graft copolymer Polymers 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- RRAMGCGOFNQTLD-UHFFFAOYSA-N hexamethylene diisocyanate Chemical compound O=C=NCCCCCCN=C=O RRAMGCGOFNQTLD-UHFFFAOYSA-N 0.000 description 1
- 229920006158 high molecular weight polymer Polymers 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 239000012510 hollow fiber Substances 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 239000012456 homogeneous solution Substances 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- UACSZOWTRIJIFU-UHFFFAOYSA-N hydroxymethyl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCO UACSZOWTRIJIFU-UHFFFAOYSA-N 0.000 description 1
- GJIDOLBZYSCZRX-UHFFFAOYSA-N hydroxymethyl prop-2-enoate Chemical compound OCOC(=O)C=C GJIDOLBZYSCZRX-UHFFFAOYSA-N 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- IQPQWNKOIGAROB-UHFFFAOYSA-N isocyanate group Chemical group [N-]=C=O IQPQWNKOIGAROB-UHFFFAOYSA-N 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 206010023332 keratitis Diseases 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 150000002734 metacrylic acid derivatives Chemical class 0.000 description 1
- FQPSGWSUVKBHSU-UHFFFAOYSA-N methacrylamide Chemical compound CC(=C)C(N)=O FQPSGWSUVKBHSU-UHFFFAOYSA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 239000007758 minimum essential medium Substances 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- DFENKTCEEGOWLB-UHFFFAOYSA-N n,n-bis(methylamino)-2-methylidenepentanamide Chemical compound CCCC(=C)C(=O)N(NC)NC DFENKTCEEGOWLB-UHFFFAOYSA-N 0.000 description 1
- OVHHHVAVHBHXAK-UHFFFAOYSA-N n,n-diethylprop-2-enamide Chemical compound CCN(CC)C(=O)C=C OVHHHVAVHBHXAK-UHFFFAOYSA-N 0.000 description 1
- VQGWOOIHSXNRPW-UHFFFAOYSA-N n-butyl-2-methylprop-2-enamide Chemical compound CCCCNC(=O)C(C)=C VQGWOOIHSXNRPW-UHFFFAOYSA-N 0.000 description 1
- FIBUWQFQYAAXHD-UHFFFAOYSA-N n-cyclopropyl-2-methylprop-2-enamide Chemical compound CC(=C)C(=O)NC1CC1 FIBUWQFQYAAXHD-UHFFFAOYSA-N 0.000 description 1
- LCXIFAOALNZGDO-UHFFFAOYSA-N n-cyclopropylprop-2-enamide Chemical compound C=CC(=O)NC1CC1 LCXIFAOALNZGDO-UHFFFAOYSA-N 0.000 description 1
- SWPMNMYLORDLJE-UHFFFAOYSA-N n-ethylprop-2-enamide Chemical compound CCNC(=O)C=C SWPMNMYLORDLJE-UHFFFAOYSA-N 0.000 description 1
- 230000017066 negative regulation of growth Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000005709 nerve cell growth Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 102000041788 p53 family Human genes 0.000 description 1
- 108091075611 p53 family Proteins 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 1
- 229920000233 poly(alkylene oxides) Polymers 0.000 description 1
- 229920000172 poly(styrenesulfonic acid) Polymers 0.000 description 1
- 229920002432 poly(vinyl methyl ether) polymer Polymers 0.000 description 1
- 229920002246 poly[2-(dimethylamino)ethyl methacrylate] polymer Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229940005642 polystyrene sulfonic acid Drugs 0.000 description 1
- 229920002717 polyvinylpyridine Polymers 0.000 description 1
- 239000012286 potassium permanganate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical compound NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 210000003786 sclera Anatomy 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- VSIVTUIKYVGDCX-UHFFFAOYSA-M sodium;4-[2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)tetrazol-2-ium-5-yl]benzene-1,3-disulfonate Chemical compound [Na+].COC1=CC([N+]([O-])=O)=CC=C1[N+]1=NC(C=2C(=CC(=CC=2)S([O-])(=O)=O)S([O-])(=O)=O)=NN1C1=CC=C([N+]([O-])=O)C=C1 VSIVTUIKYVGDCX-UHFFFAOYSA-M 0.000 description 1
- 210000001988 somatic stem cell Anatomy 0.000 description 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
- 229960000553 somatostatin Drugs 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 229960002317 succinimide Drugs 0.000 description 1
- DLYUQMMRRRQYAE-UHFFFAOYSA-N tetraphosphorus decaoxide Chemical compound O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000003685 thermal hair damage Effects 0.000 description 1
- 210000001578 tight junction Anatomy 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 229960003726 vasopressin Drugs 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- NLVXSWCKKBEXTG-UHFFFAOYSA-N vinylsulfonic acid Chemical compound OS(=O)(=O)C=C NLVXSWCKKBEXTG-UHFFFAOYSA-N 0.000 description 1
- 239000003190 viscoelastic substance Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- C12N5/0623—Stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- C12N5/0621—Eye cells, e.g. cornea, iris pigmented cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/30—Synthetic polymers
Definitions
- the present invention relates to a method for cultivating cells derived from corneal limbal tissue and cells derived from corneal limbal tissue.
- Cornea is located at the front of the eyeball and constitutes the external wall of the eyeball along with the sclera.
- the cornea is also a transparent tissue without any blood vessels, which not only functions as a lens to permeate and refract surrounding light into the eye, but also contributes to obtaining better visual acuity by forming a smooth surface together with the lacrimal fluid.
- One to two layers of cortical cells of corneal epithelium present at the topmost layer of the cornea are in a particular adherence structure called tight junction where intercellular space is tightly closed, and has barrier function to prevent substances from penetrating inside from the lacrimal fluid side. This barrier function makes it possible to limit the permeation of water-soluble substance into the cornea and also to prevent bacterial invasion.
- corneal epithelial cells play an extremely important role in maintaining the transparency of the cornea and the homeostasis of the eyeball.
- the cornea may become clouded and lose its transparency due to disorders, for example keratitis, corneal ulcer, pathological conditions such as puncture, accidents, etc.
- disorders for example keratitis, corneal ulcer, pathological conditions such as puncture, accidents, etc.
- therapy by corneal transplant is performed.
- patient's cornea which had lost its transparency is removed, and a transparent cornea is
- corneal transplantations some diseases cannot be dealt with simply by such corneal transplantations. These include, for example, Stevens-Johnson syndrome, pemphigus of the eye, chemical injury, and burns.
- keratoconjunctival epithelial cells repeatedly divide everyday, old cells shed off, and new cells are regenerated from stem cells.
- stem cell tissue which regenerates the corneal epithelium is called "corneal limbal tissue", and is confined in the borderline of the iris and the white of the eye and is under a particular environment of being exposed to the surroundings.
- the stem cell tissue per se is damaged in some way and becomes eradicated. Due to the eradication of the stem cell tissue, the deficient region becomes covered by the conjunctival epithelium which is present around it, leading to lack of transparency and radical decline in visual acuity.
- transplantated cornea cannot be retained for a long period by simply transplanting a cornea, since corneal limbus has been depleted. It is therefore necessary to transplant the corneal limbus as well to provide permanent reconstruction of the eye surface.
- One method developed to transplant the corneal limbus is a transplantation method using amniotic membrane (Medical Asahi, September, 1999, p62-65; N Engl J Med, 340:1697-1703, 1999). Also in Japanese Patent Laid-Open No.
- corneal limbal tissue which is stem cell tissue of corneal epithelial cells, or conjunctival perimeter, which is stem cell tissue of conjunctival epithelial cells, onto amniotic membrane of which the sponge layer and the epithelial layer are removed, and then growing the epithelial cells so that they cover the surface of amniotic membrane, are disclosed.
- amniotic membrane Since the amniotic membrane has thick basal membrane, it acts as a matrix which keratoconjunctival epithelial cells grow and differentiate on.
- the amniotic membrane used for the transplantation method needs to be obtained from the placenta of, for example, a pregnant woman who has undergone Caeserian section, and therefore has been difficult to obtain. Even if it is obtained, there may exist risks such as immune rejection to the donated amniotic membrane and infection from the amniotic membrane.
- the present invention is intended to overcome the above problems.
- the objects of the present invention are to provide corneal limbal stem cells or differentiated cells from corneal limbal stem cells which can be used for treating diseases associated with cornea without using amniotic membrane tissue, and to provide a method of cultivating corneal limbal stem cells without using amniotic membrane tissue.
- corneal limbal stem cells which can be used to treat diseases associated with cornea
- a method for cultivating corneal limbal stem cells characterized in that the method comprises the steps of: embedding the corneal limbal tissue within an aqueous solution in a low temperature sol state wherein the aqueous solution contains at least a hydrogel-forming polymer showing thermo-reversible sol-gel transition and wherein the aqueous solution is in a sol state at a low temperature and is in a gel state at a high temperature; heating the said aqueous solution to cultivate the said corneal limbal tissue within the said hydrogel in a high temperature gel state so that the corneal limbal stem cells spread and grow outside of the said corneal limbal tissue; cooling the said hydrogel to return from the gel state to a low temperature sol state; and collecting the spread and grown cells derived from corneal limbal tissue.
- Figure 1 shows phase contrast microscopic observation image (10 times) of corneal limbal tissue from donor A on day 6 when cultivated in the hydrogel according to the present invention.
- Figure 2 shows phase contrast microscopic observation image (10 times) of corneal limbal tissue from donor A on day 8 when cultivated in the hydrogel according to the present invention.
- Figure 3 shows phase contrast microscopic observation image (20 times) of corneal limbal tissue from donor A on day 10 when cultivated in the hydrogel according to the present invention.
- Figure 4 shows tissue image (10 times) of corneal limbal tissue from donor A
- Figure 5 shows tissue image (10 times) of corneal limbal tissue from donor B HE stained after 5 days of cultivation in the hydrogel according to the present invention.
- Figure 6 shows comparison of cell growth activity when corneal limbal tissue from donor J was cultivated in each of in the hydrogel according to the present invention, on amniotic membrane tissues, and on cultivation plates
- Figure 7 shows comparison of cell growth activity when corneal limbal tissue from donor K was cultivated in each of in the hydrogel according to the present invention, on amniotic membrane tissues, and on cultivation plates.
- Figure 8 shows comparison of cell growth activity when corneal limbal tissue from donor L was cultivated in each of in the hydrogel according to the present invention, on amniotic membrane tissues, and on cultivation plates.
- Figure 9 shows immunoperoxidase staining of donor B / 04 cultivated embedded in Mebiol Gel -P63 & Connexin 43 -POSITIVE; ABCG2 & INTEGRIN ⁇ - Negative
- Figure 10 shows immunoperoxidase staining of Donor C / 04 cultivated embedded in Mebiol Gel P63- Negative; ABCG2 , Connexin 43 & Integrin ⁇ - Cells are POSITIVE,
- Figure -11 shows immunoperoxidase staining of Donor D / 04 cultivated inside the Mebiol Gel P63, Connexin 43 & Integrin ⁇ - cells are POSTIVE; ABCG2 — Negative:
- Figure 12 shows immunoperoxidase staining of Donor E / 04 cultivated inside the Mebiol Gel P 63, ABCG2 & Connexin 43 - POSTIVE; Integrin ⁇ - Negative
- Figure 13 shows immunofluorescence staining of Donor I/ 04 cultivated inside the Mebiol Gel Immunomarker staining was done on the cells harvested day -11 Apple green staining cells - Positive for the specific markers
- Figure 14 shows donor J / 04 - Immunomarker studies Immunofluorescence staining was done on the cells harvested day -10th day Apple green staining cells - Positive for ABCG2 & Connexin - 43 DETAILED DESCRIPTION OF THE INVENTION :
- cells derived from corneal limbal tissue comprise corneal limbal stem cells as well as differentiated cells from corneal limbal stem cells.
- corneal limbal stem cells are cells derived from corneal limbal tissue and are positive in p63 protein immunostaining.
- p63 belongs to tumor suppressor gene p53 family and has a structure similar to p53.
- p63 is a transcription factor which plays an important role in morphogenesis. A plurality of isoforms for p63 exist, and are classified roughly into TAp63 having a transcription activation domain at the N-terminus and DNp63 which do not have the domain.
- DNp63 gene is expressed within the nucleus of keratinocytes having growing activity.
- corneal limbal stem cells having pluripotency are cells derived from corneal limbal tissue and are positive in ABCG2 immunostaining.
- ABCG2 ATP -binding Cassette superfamily G member 2
- transient growing cells are cells derived from corneal limbal tissue and are positive in connexin 43 immunostaining.
- Connexin is a gap junction protein, which forms a gap junction that transports low molecular weight proteins between cells.
- Connexin 43 is a protein having a molecular weight of 43 kDa and is known to be expressed upon differentiation of transient growing cells.
- mature corneal epithelial cells are cells derived from corneal limbal tissue and are positive in integrin ⁇ immunostaining.
- Integrin is a receptor for cell adhesion factor and is a heterodimeric protein composed of ⁇ - and ⁇ -chain subunits. Integrin ⁇ is known as a marker for epithelial cells showing transient growing activity.
- mouse monoclonal antibody IgG 2a against integrin ⁇ 4 (A9) can be used.
- any of the above cells derived from corneal limbal tissue can be obtained, although it is particularly preferred to obtain among diseases associated with cornea corneal limbal stem cells effective for dysfunctions of corneal limbal stem cells and corneal limbal stem cells having pluripotency.
- the hydrogel-forming polymer constituting the hydrogel according to the present invention refers to a polymer has a property such that it can form a hydrogel which has a crosslinking or network structure by retaining water (in the inside thereof) on the basis of such a structure.
- the "hydrogel” refers to a gel, which comprises, at least a crosslinked or network structure comprising a polymer, and water (as a dispersion liquid) supported or retained by such a structure.
- the "dispersion liquid” retained in the crosslinked or network structure is not particularly limited, as long as it is a liquid comprising water as a main or major component. More specifically, the dispersion liquid may for example be either of water per se, an aqueous solution and/or water-containing liquid.
- the water-containing liquid may preferably contain 80 parts or more, more preferably 90 parts or more of water, based on the total 100 parts of the water-containing liquid. (Sol-gel transition temperature)
- sol state In the present invention, the terms "sol state”, “gel state” and “sol-gel transition temperature” are defined in the following manner. With respect to these definitions, a paper (Polymer Journal, 18(5), 411-416 (1986)) may be referred to. 1 ml of a hydrogel in a sol state is poured into a test tube having an inside diameter of 1 cm, and is left standing for 12 hours in a water bath which is controlled at a predetermined temperature (constant temperature).
- the above polymer solution is defined as a "sol state" at the above-mentioned predetermined temperature.
- the above polymer solution is defined as a "gel state" at the above-mentioned predetermined temperature.
- the thus determined transition temperature is defined as a "sol-gel transition temperature”.
- the above sol-gel transition temperature at which the "gel state” is converted into the "sol state” while gradually decreasing the "predetermined temperature” (e.g., in 1 0 C decrement).
- the definition and measurement of the "sol state,” “gel state,” and “sol-gel transition temperature” may also be carried out as mentioned below according to the definition and method described in a publication (H. Yoshioka et al, Journal of Macromolecular Science, A31(l), 113 (1994)).
- the dynamic elastic modulus of a sample at an observed frequency of 1 Hz is determined by gradually shifting the temperature from a low temperature side to a high temperature side (1°C/1 min).
- the sol-gel transition temperature is defined as a temperature at which the storage elastic modulus (G', elastic term) of the sample exceeds the loss elastic modulus (G", viscous term).
- the sol state is defined as a state in which G" > G' is satisfied
- the gel state is defined as a state in which G" ⁇ G' is satisfied.
- the following measuring conditions can preferably be used.
- Measuring apparatus (trade name): Stress controlled-type rheometer (model: CSL-500, mfd. by Carri-Med Co.)
- sample solution or dispersed liquid (as a concentration of a "polymer compound having a sol-gel transition temperature"): 10% (by weight)
- Amount of sample solution about 0.8 g
- Shape and size of cell for measurement acrylic parallel disk (diameter: 4.0 cm), gap: 600 ⁇ m
- the above sol-gel transition temperature may preferably be higher than 0 0 C and not higher than 45 °C, more preferably, higher than 0 0 C and not higher than 42 0 C ( particularly not lower than 4 °C and not higher than 40 0 C) in view of the prevention of a thermal damage to cells or a tissue of a living organism.
- the hydrogel material having such a preferred sol-gel transition temperature may easily be selected from specific compounds as described below, according to the above-mentioned screening method (method of measuring the sol-gel transition temperature).
- the above-mentioned sol-gel transition temperature (a 0 C) between the temperature at the time of the culturing of the cell or tissue (b 0 C), and the temperature at the time of the cooling for the inoculation, mixing or recovery of the cell or tissue (c 0 C).
- the above-mentioned three kinds of temperatures of a 0 C, b 0 C and c 0 C may preferably have a relationship of b > a > c.
- the value of (b - a) may preferably be 1 - 40 0 C, more preferably 2 - 30 0 C.
- the value of (a - c) may preferably be 1 - 40 0 C, more preferably 2 - 30 0 C.
- the hydrogel based on the carrier according to the present invention shows a behavior in a solid-like manner toward a higher frequency
- the carrier shows a behavior in a liquid-like manner toward a lower frequency.
- the property of the carrier for following the movements may preferably be measured according to the following method. (Method of measuring movement-following property)
- the carrier according to the present invention comprising a hydrogel-forming polymer in a sol state (i.e., at a temperature lower than the sol-gel transition temperature) is poured into a test tube having an inside diameter of 1 cm, in an amount of the carrier corresponding to a volume of 1 rnL as the resultant hydrogel. Then, the above test tube is left standing for 12 hours in a water bath which is controlled at a temperature which is sufficiently higher than the sol-gel transition temperature of the carrier (e.g., a temperature which is 10 0 C higher than the sol-gel transition temperature), whereby the hydrogel material is converted into a gel state.
- a temperature which is sufficiently higher than the sol-gel transition temperature of the carrier e.g., a temperature which is 10 0 C higher than the sol-gel transition temperature
- T may preferably be 1 minute to 24 hours, more preferably 5 minutes to 10 hours;
- the gel property of the hydrogel based on the carrier according to the present invention may preferably be determined by measuring the steady-state flow kinematic viscosity thereof.
- the steady-state flow kinematic viscosity ⁇ (eta) may be measured by using a creep experiment.
- the Steady-state flow kinematic viscosity ⁇ is defined as the ratio of the shear stress and the shear rate at this time.
- This Steady-state flow kinematic viscosity can also be called Newtonian viscosity. However, it is required that the Steady-state flow kinematic viscosity is determined in the linear region wherein the viscosity little depends on the shear stress.
- a stress-controlled type viscoelasticity-measuring apparatus (model: CSL-500, mfd. by Carri-Med Co., USA) is used as the measuring apparatus, and an acrylic disk (having a diameter of 4 cm) is used as the measuring device, and the resultant creep behavior (delay curve) is measured for at least five minutes with respect to a sample having a thickness of 600 ⁇ m.
- the sampling time is once per one second for the initial 100 seconds, and once per ten seconds for subsequent period.
- the hydrogel based on the carrier according to the present invention may preferably have an ⁇ of 5xl0 3 -5xl0 6 Pa sec, more preferably 8xl0 3 -2xl0 6 Pa sec, particularly, not less than IxIO 4 Pa sec and not more than 1x10 Pa sec, at a temperature which is about
- Shoten, 1985 may be referred to).
- the ratio ⁇ (tan ⁇ ) s / (tan ⁇ ) L ⁇ between the above (tan ⁇ ) s and (tan ⁇ ) L may preferably be less than 1 (mire preferably 0.8 or less, particularly, 0.5 or less).
- Temperature a temperature which is about 10 0 C higher than the sol-gel transition temperature of the carrier
- Measuring apparatus Stress controlled-type rheometer (model: CSL-500, mfd. by Carri-Med Co., USA) (Control of residual property in living body)
- the hydrogel according to the present invention is mainly intended to be used in vitro. However, depending on its usage (for example, when a tissue which has been grown by using the hydrogel according to the present invention are returned into a living body), there are cases where the control of the in vivo remaining property of the hydrogel is preferred.
- the sol-gel transition temperature of the hydrogel according to the present invention is decreased, the hydrogel tends to remain in a living body for a long period of time. In contrast, if the sol-gel transition temperature of the hydrogel according to the present invention is increased, the hydrogel tends to rapidly disappear in a living body.
- the hydrogel tends to remain in a living body for a long period of time. If the concentration of the hydrogel-forming polymer in the hydrogel is decreased, the hydrogel tends to rapidly disappear in a living body.
- the storage elastic modulus (G') of the hydrogel at a living body temperature (37 0 C) is increased. Further, if the concentration of the hydrogel-forming polymer in the hydrogel is increased, the storage elastic modulus (G') of the hydrogel at a living body temperature (37 0 C) is increased. That is, in order to control the residual property of the hydrogel in a living body, G' at 37°C may be controlled.
- the following measuring conditions can preferably be used.
- Measuring apparatus (trade name): Controlled stress rheometer CSL 500 mfd. by Carri-Med Co.
- Amount of sample solution about 0.8 g
- Shape and size of cell for measurement acryl parallel disk (diameter: 4.0 cm), gap: 600 ⁇ m
- the relationship between the residual period for the hydrogel according to the present invention in a living body, and G' is also dependent on the site or portion therefor in a living body.
- the relationship between the residual period for the hydrogel in the abdominal cavity and G' at an observation frequency of 1 Hz is as follows. That is, the desired range of G' for providing the hydrogel disappearance of 3 days or less is 10 to 500 Pa.
- the desired range of G' for providing the hydrogel disappearance of the hydrogel remaining for a period of not less than 3 days and not more than 14 days is 200 to 1,500 Pa.
- the desired range of G 1 for providing the hydrogel disappearance of the hydrogel remaining for a period of more than 14 days is 400 to 10,000 Pa.
- fibroblasts exhibit substantially no growth in the hydrogel based on the hydrogel-forming polymer constituting the carrier.
- the fibroblasts are significantly grown so as to provide a change thereof into an arboroid form peculiar to the fibroblasts (e.g., Jyunpei Enami, Baiyosaibo o Mochiiru Hoho (Method of using cultured cells); edited by Meiji Saito, Saibogai Matrix (Extracellular Matrix), published by Medical Review Co,, Ltd. (Tokyo), 1996, pp. 108-115, may be referred to)
- fibroblasts maintain a spherical form thereof and they exhibit substantially no growth. (Presumed mechanism for inhibition of growth of fibroblasts)
- a fibroblast has a property that it recognizes a monolayer culture, i.e., the surface of a supporting medium, and adheres thereto, whereby it actively grows two-dimensionally.
- a collagen gel has a structure such that a large number of collage molecules (molecular weight: 300,000) with a length of 300 nm and a diameter of 1.5 nm are aggregated and are regularly arranged, and that they become collagen fibril and form a network structure in water.
- the collagen gel Since this network structure is greater than the wavelength of visible radiation (400 nm or more), the collagen gel generally looks clouded or turbid.
- the collagen gel is used as a carrier for a three-dimensional culture. It is presumed that since a fibroblast recognizes the surface of a thick collagen fibril as a supporting medium and adheres thereto, this cell significantly grows two-dimensionally in the collagen gel.
- the hydrogel is constituted such that a hydrogel-forming polymer in a molecular state forms a three-dimensional network structure, the heterogeneity of the structure is smaller than that of the wavelength of visible radiation, and it has a relatively high transparency. Accordingly, it is presumed that fibroblasts do not clearly recognize the surface of a two-dimensional supporting medium in the material according to the present invention, and that as a result, an excessive growth of fibroblasts is inhibited in the material according to the present invention. (Evaluation of growing property of fibroblasts)
- fibroblasts can be evaluated by the following method (with respect to the details thereof of this method, e.g., Tsuyoshi Yoshikawa, Ken Tsukikawa, St. Marianna University, School of Medicine, Journal Vol. 28, No. 4, pp. 161-170 (2000) may be referred to).
- a hydrogel-forming polymer constituting the cell or tissue-culturing carrier according to the present invention is dissolved in a culture solution such as RPMI- 1640 (Life Technologies, N. Y., USA) at a low temperature (for example, 4 0 C), under stirring. Thereafter, normal human lung fibroblasts (NHLF, mfd.
- the growth of fibroblasts is observed along with the elapse of time (e.g., on the Oth, 1st, 3rd and 7th days after the day of culture), by using a phase-contrast microscope. (Growth rate of fibroblasts)
- the growth rate of fibroblasts can be determined in the culturing period by the following method using an enzyme activity.
- a 24-well plate as described above is used, and fibroblasts are cultured thereby for a certain period of time in the cell or tissue-culturing carrier according to the present invention, and the temperature of the carrier is decreased to a temperature lower than the sol-gel transition temperature thereof (e.g., a temperature which is 10 0 C lower than the sol-gel transition temperature), so as to dissolve the carrier.
- 50 ⁇ l of a WST-8 reagent mfd. by Dojin Kagaku (Dojindo Laboratories)
- a reagent for determining the activity of succinate dehydrogenase is added to each of the wells.
- the thus prepared 24-well plate is subjected to a reaction at a temperature which is lower than the sol-gel transition temperature (e.g., a temperature which is 10 0 C lower than the sol-gel transition temperature, for example, at 10 0 C) for 10 hours, and it is then retained at about 4 0 C for 1 hour, so that a completely homogenous aqueous solution is prepared. 200 ⁇ l of each of the thus obtained aqueous solution is poured into each well of a 96-well plate. The resultant absorbance (OD (450)) is measured at 450 nm
- the growth rate (OD L OD,-) is ⁇ more preferably within the range of not lower than 80 % and not higher than 150 %, and particularly preferably within the range not lower than 90 % and not higher than 120 %.
- the growth of intended cells is not inhibited relatively, while the growth of fibroblasts is inhibited.
- the ratio (P T /P F ) between the growth rate of the intended- cells P ⁇ and the growth rate of the above fibroblasts P F may preferably be 1.1 or more.
- the ratio (P J /P F ) may more preferably be 1.5 or more, and particularly preferably 2 or more.
- the growth rate P ⁇ of the intended cells can be determined as follows.
- the growth rate of cells other than fibroblasts P ⁇ may be determined in the same manner as in the above determination of the growth rate of fibroblasts P F except that human colon cancer cells (SW-948, trade name: Colonic Adenoma Cell Lines, mfd. by Dainippon Pharmaceutical Co., Ltd.) are used instead of normal human lung fibroblasts (NHLF) used in the above determination of the fibroblast growth rate P F .
- human colon cancer cells SW-948, trade name: Colonic Adenoma Cell Lines, mfd. by Dainippon Pharmaceutical Co., Ltd.
- NHLF normal human lung fibroblasts
- the hydrogel-forming polymer usable for the carrier according to the present invention is not particularly limited, as long as the polymer exhibits the above-mentioned thermo -reversible sol-gel transition (that is, as long as it has a sol-gel transition temperature). It is preferable to achieve a preferred sol-gel transition temperature by adjusting the cloud point of a plurality of blocks having a cloud point and the cloud point of a hydrophilic block in the hydrogel-forming polymer, the compositions, hydrophobicity or hydropb ⁇ licity of both types of blocks, and/or their ' molecular weights, in view of easy exhibition of a preferred sol-gel transition at a physiological temperature (about O 0 C to 42 0 C).
- polyalkylene-oxide block copolymer represented by block copolymers comprising polypropylene oxide portions and polyethylene oxide portions; etherified (or ether group-containing) celluloses such as methyl cellulose and hydroxypropyl cellulose; chitosan derivatives (K. R. Holme, et al. Macromolecules, 24, 3828 (1991)), etc.
- Pluronic F- 127 trade name, mfd. by BASF Wyandotte Chemical Co.
- the molecular weight of the Pluronic F-127 is relatively low, and it shows an extremely high osmotic pressure at a high concentration of not less than about 20 wt. %, and simultaneously the Pluronic F-127 may easily permeate the cell membranes, whereby the Pluronic F-127 can adversely affect cells and microorganisms.
- the sol-gel transition temperature thereof is as high as about 45 0 C or higher (N. Sarkar, J. Appl. Polym. Science, 24, 1073, (1979)).
- such an etherified cellulose is less liable to form a gel at body temperature (about 38 0 C), and therefore it is difficult to use such a material for the above-mentioned purposes according to the present invention.
- a conventional polymer having a sol-gel transition temperature in an aqueous solution thereof, and reversibly assuming a sol state at a temperature lower than the above transition temperature is simply used, the following problems are posed: (1) If the polymer is once converted into a gel state at a temperature higher than the sol-gel transition temperature, the resultant gel is dissolved when water is further added thereto;
- the polymer has a sol-gel transition temperature higher than the body temperature (in the neighborhood of 38 0 C), and therefore the polymer assumes a sol state in the interior of a living body;
- a polymer having a sol-gel transition temperature of higher than 0 0 C and not higher than 42 0 C e.g., a polymer which comprises a plurality of polymer chains having a cloud point, and a hydrophilic polymer chain block which has
- the hydrogel-forming polymer preferably usable as the carrier according to the present invention may preferably comprise a combination of plural hydrophobic blocks having a cloud point, and a hydrophilic block bonded thereto.
- the presence of the hydrophilic block is preferred in view of the provision of the water-solubility of the hydrogel material at a temperature lower than the sol-gel transition temperature.
- the presence of the plural hydrophobic block having a cloud point is preferred in view of the conversion of the hydrogel material into a gel state at a temperature higher than the sol-gel transition temperature. In other words, the blocks having a cloud point become .
- the cloud point based on the hydrophobic bonds corresponds to the above-mentioned sol-gel transition temperature
- the cloud point corresponds to the sol-gel transition temperature. This is because the cloud point of the above-mentioned "blocks having a cloud point" is generally influenced by the bonding between the hydrophilic block and the blocks having a cloud point.
- the hydrogel to be use in the present invention utilizes a property of hydrophobic bonds such that they are not only strengthened along with an increase in temperature, but also the change in the hydrophobic bond strength is reversible with respect to the temperature.
- the hydrogel-forming polymer may preferably have a plurality of "blocks having cloud point".
- the hydrophilic block in the hydrogel-forming polymer has a function of causing the hydrogel-forming polymer to be changed into a water-soluble state at a temperature lower than sol-gel transition temperature.
- the hydrophilic block also has a function of providing the state of an aqueous (or water-containing) gel, while preventing the aggregation and precipitation of the hydrogel material due to an excess increase in the hydrophobic binding force at a temperature higher than the transition temperature.
- the plural block having a cloud point may preferably comprise a polymer block which shows a negative solubility-temperature coefficient with respect to water.
- such a polymer may preferably be one selected from the group consisting of: polypropylene oxide, copolymers comprising propylene oxide and another alkylene oxide, poly N-substituted acrylamide derivatives, poly N-substituted methacrylamide derivatives, copolymers comprising an N-substituted acrylamide derivative and an N-substituted methacrylamide derivative, polyvinyl methyl ether. and partially-acetylated product of polyvinyl alcohol.
- a polypeptide comprising a hydrophobic . amino acid and a hydrophilic amino acid it is effective to use a polypeptide comprising a hydrophobic . amino acid and a hydrophilic amino acid, as the block having a cloud point.
- a polyester-type biodegradable polymer such as polylactic acid or polyglycolic acid can also be used as a block having a cloud point which is decomposed and absorbed in a living body.
- the above polymer (block having a cloud point) has a cloud point of higher than 4 0 C and not higher than 40 0 C, in view of the provision of a polymer (compound comprising a plurality of blocks having a cloud point, and a hydrophilic block bonded thereto) to be used in the present invention having a sol-gel transition temperature of higher than 4 0 C and not higher than 40 0 C.
- the cloud point e.g., by the following method. That is. an about 1 wt.%-aqueous solution of the above polymer (block having a cloud point) is cooled to be converted into a transparent homogeneous solution, and thereafter the temperature of the solution is gradually increased (temperature increasing rate: abou.: 1 °C/min.), and the point at which the solution first shows a cloudy appearance i • defined as the cloud point.
- temperature increasing rate abou.: 1 °C/min.
- N-substituted methacrylamide derivatives are described below.
- Poly-N-acryloyl piperidine Poly-N-n-propyl methacrylamide
- the above polymer may be either a homopolymer or a copolymer comprising a monomer constituting the above polymer and "another monomer".
- the "another monomer” to be used for such a purpose may be either a hydrophilic monomer, or a hydrophobic monomer.
- the resultant cloud point may be increased.
- the resultant cloud point may be decreased.
- a polymer having a desired cloud point may also be obtained by selecting such a monomer to be used for the copolymerization.
- a desired cloud point e.g., a cloud point of higher than 4 0 C and not higher than 40 °C
- hydrophilic monomer may include: N-vinyl pyrrolidone, vinyl pyridine, acrylamide, methacrylamide, N-methyl acrylamide, hydro xyethyl methacrylate, hydroxyethyl acrylate, hydroxymethyl methacrylate, hydroxymethyl acrylate, methacrylic acid and acrylic acid having an acidic group, and salts of these acids, vinyl sulfonic acid, styrenesulfonic acid, etc., and derivatives having a basic group such as N,N-dimethylaminoethyl methacrylate, N,N-diethylaminoethyl methacrylate, N,N-dirnethylaminopropyl acrylamide, salts of these derivatives, etc.
- the hydrophilic monomer to be usable in the present invention is not restricted to these specific examples. (Hydrophobic monomer)
- hydrophobic monomer may include: acrylate derivatives and methacrylate derivatives such as ethyl acrylate, methyl methacrylate, and glycidyl methacrylate; N-substituted alkyl methacrylamide derivatives such as N-n-butyl methacrylamide; vinyl chloride, acrylonitrile, styrene, vinyl acetate, etc.
- the hydrophobic monomer to be usable in the present invention is not restricted to these specific examples.
- hydr ⁇ philic block to be combined with (or bonded to) the above-mentioned block having a cloud point may include: methyl cellulose, dextran, polyethylene oxide, polyvinyl alcohol, poly N-vinyl pyrrolidone, polyvinyl pyridine, polyacrylamide, polymethacrylamide, poly N-methyl acrylamide, polyhydroxymethyl acrylate, polyacrylic acid, polymethacrylic acid, polyvinyl sulfonic acid, polystyrene sulfonic acid, and salts of these acids; poly N,N-dimethylaminoethyl methacrylate, poly N,N-diethylaminoethyl methacrylate, poly N,N-dimethylaminopropyl acrylamide, and salts of these, etc.
- the process for combining the above block having a cloud point with the hydrophilic block is not particularly limited.
- the block having a cloud point and the hydrophilic block may also be combined or bonded with each other by preliminarily introducing reactive functional groups (such as hydroxyl group, amino group, carboxyl group, and isocyanate group) into both kinds of the blocks, and combining these blocks by using a chemical reaction. At this time, it is usual to introduce a plurality of reactive functional groups into the hydrophilic block.
- reactive functional groups such as hydroxyl group, amino group, carboxyl group, and isocyanate group
- polypropylene oxide having a cloud point and the hydrophilic block may be combined or bonded with each other by repetitively subjecting polypropylene oxide and a monomer constituting the above "other water-soluble block” (such as ethylene oxide) to a stepwise or consecutive polymerization, to thereby obtain a block copolymer comprising polypropylene oxide and a water-soluble block (such as polyethylene oxide) combined therewith.
- a monomer constituting the above "other water-soluble block” such as ethylene oxide
- Such a block copolymer may also be obtained by introducing a polymerizable group (such as acryloyl group) into the terminal of polypropylene oxide, and then copolymerizing therewith a monomer constituting the hydrophilic block.
- a polymerizable group such as acryloyl group
- a polymer usable in the present invention may be obtained by introducing a functional group which is reactive in a bond-forming reaction with the terminal functional group of polypropylene oxide (such as hydroxyl group) into a hydrophilic block, and reacting the resultant hydrophilic block and the polypropylene oxide.
- a hydrogel-forming polymer usable in the present invention may be obtained by connecting materials such as one comprising polypropylene glycol and polyethylene glycol bonded to both terminals thereof (such as Pluronic F-127; trade name, mfd. by Asahi Denka Kogyo K.K.).
- the hydrogel-forming polymer comprises a block having a cloud point
- the polymer may completely be dissolved in water so as to assume a sol state, since the above-mentioned "block having a cloud point" present -in the polymer molecule is water-soluble together with the hydrophilic block.
- the "block having a cloud point" present in the polymer molecule becomes hydrophobic so that separate molecules of the polymer are associated or aggregated with each other due to a hydrophobic interaction.
- the hydrophilic block is water-soluble even at this time (i.e., even when heated up to a temperature higher than the cloud point), and therefore, the polymer according to the present invention in water is formed into a hydrogel having a three-dimensional network structure wherein hydrophobic association portions between the blocks having a cloud point constitute the crosslinking points.
- the resultant hydrogel is again cooled to a temperature lower than the cloud point of the "block having a cloud point" present in the polymer molecule, the block having a cloud point becomes water-soluble and the above crosslinking points due to the hydrophobic association are released or liberated so that the hydrogel structure disappears, whereby the polymer according to the present invention is again formed into a complete aqueous solution.
- the sol-gel transition in the ' polymer according to the present invention is based on the reversible hydrophilic-hydrophobic conversion in the block having a cloud point present in the polymer molecule at the cloud point, and therefore the transition has a complete reversibility in accordance with a temperature change. (Solubility of gel)
- the hydrogel-forming polymer according to the present invention comprising at least a polymer having a sol-gel transition temperature in an aqueous solution thereof, substantially shows a water insolubility at a temperature (d 0 C) higher than the sol-gel transition temperature, and reversibly shows water solubility at a temperature (e 0 C) lower than the sol-gel transition temperature.
- the above-mentioned temperature (d 0 C) may preferably be a temperature which is at least 1 °C, more preferably at least 2 0 C (particularly preferably, at least 5 11 C) higher than the sol-gel transition temperature.
- the above-mentioned "substantial water insolubility" may preferably be a state wherein the amount of the above polymer to be dissolved in lOO ml of water at the above temperature (d °C) is 5.0 g or less (more preferably 0.5 g or less, particularly preferably 0.1 g or less).
- the above-mentioned temperature (e 0 C) may preferably be a temperature which is at least 1 0 C, more preferably at least 2 0 C (particularly preferably, at least 5 0 C) lower than the sol-gel transition temperature, in terms of the absolute values of these temperatures.
- the above-mentioned "water solubility" may preferably be a state wherein the amount of the above polymer to be dissolved in 100 ml of water at the above temperature (e 0 C) is 0.5 g or more (more preferably 1.0 g or more).
- the above "to show a reversible water solubility” refers to a state wherein an aqueous solution of the above hydrogel-forming polymer shows the above-mentioned water solubility at a temperature lower than the sol-gel transition temperature, even after the polymer is once formed into a gel state (at a temperature higher than the sol-gel transition temperature).
- a 10%-aqueous solution of the above polymer may preferably show a viscosity of 10 - 3,000 Pa s (10 - 3,000 centipoises), more preferably, 50 - 1,000 Pa s (50 - 1,000 centipoises) at 5 0 C.
- Such a viscosity may preferably be measured, e.g., under the following measurement conditions: Viscometer: Stress-controlled type rheometer (model: CSL-500, mfd. by
- the resultant solution is poured into a plastic Petri dish having a diameter of 35 mm, then the dish is warmed up to a temperature of 37 0 C to form a gel having a thickness of about 1.5 mm in the dish, and the total weight of the Petri dish (f gram) containing the gel is measured. Then, the entirety of the Petri dish containing the gel is left standing in 250 ml of water at 37 0 C for 10 hours, and thereafter the total weight of the Petri dish (g gram) containing the gel is measured, to thereby determine whether the gel has been dissolved from the gel surface or not.
- the ratio of weight decrease in the gel i.e., the value of ⁇ (f-g)/f
- the value of ⁇ (f-g)/f may preferably be 5.0 % or less, more preferably 1.0 % or less (particularly preferably 0.1 % or less).
- Pluronic F- 127 comprising polypropylene oxide and polyethylene oxide bonded to both terminals thereof, the resultant gel was completely dissolved when the gel is left standing in water for several hours.
- a hydrogel-forming polymer which can be converted into a gel state at a concentration of 20% or less (more preferably 15% or less, particularly 10% or less) in terms of the concentration of the polymer based on water, i.e., ⁇ (polymer)/(polymer + water) ⁇ x 100 (%).
- the carrier according to the present invention comprises at least the above-mentioned polymer having a sol-gel transition temperature.
- the carrier may also comprise another component, as desired.
- Other components in such an embodiment may include: antibiotics, anticancer or antitumor substances, ECM such as collagen and gelatin, local chemical mediators appearing hereinafter, hormones such as insulin and growth factors, foreign genes, etc.; and other cells or tissues capable of secreting these chemical mediators and cell growth factors, etc.
- the use amount of such "other components” is not particularly limited, as long as it exhibits an intended effect and can be retained in the gel based on the hydrogel-forming polymer for a certain period of time (e.g., for a period necessary for culturing cells or tissue).
- the amount of the other component to be used may preferably be 2 parts or less, and more preferably 1 part or less, based on the total parts (10 parts) of the hydrogel-forming polymer.
- (Chemical mediator) There are some cases where the regeneration of a living organism tissue requires not only cells such as precursor cells but also various chemical mediators such as cell growth factor which promotes the differentiation or the growth of the cells. The chemical mediator is generally secreted from cells. However, in order to efficiently conduct the regeneration, it is effective to previously add such a chemical mediator to the cell or tissue-culturing carrier according to the present invention, so as to supply the chemical mediator from the outside of the living organism tissue.
- Examples of the above-mentioned chemical mediator may include: 1) local chemical mediators which can act extremely in the vicinity of the cell; T) neurotransmitters which are secreted by nerve cells and have a extremely short effective acting distance; 3) hormones which are secreted by endocrine cells and systemically act on target cells through bloodstream, etc.; and the like.
- Examples of 1) local chemical mediator as described- above may include: proteins such as nerve cell growth factors, peptides such as chemotaxis factors, amino acid derivatives such as histamine, fatty acid derivatives such as prostaglandins, etc.
- Examples of 2) neurotransmitter as described above may include: low-molecular weight substances including amino acids such as glycine, low-molecular peptides such as noradrenaline, acetylcholine, and enkephalin, etc.
- cell growth factor or hormones as described above may include: cell growth factors such as fibroblast growth factor (FGF), epithelial growth factor
- EGF vascular endothelial growth factor
- HGF hapatocyte growth factor
- proteins such as insulin, somatotropin, somatomedin, adrenocorticotropic hormone (ACTH), parathyroid hormone (PTH), and thyroid-stimulating hormone (TSH); glycoproteins, amino acid derivatives such as somatostatin, vasopressin, TSH releasing factor; steroids such as Cortisol, estradiol, testosteron; etc.
- the hydrogel according to the present invention it is possible to arbitrarily control the diffusion rate of a chemical mediator in the hydrogel.
- a hydrophilic substance and a hydrophobic substance can be diffused at different diffusion rates.
- the diffusion of a water-soluble hydrophilic substance is controlled by the molecular sieving effect of the three-dimensional network structure of the hydrogel-forming polymer. Accordingly, in order to reduce the diffusion rate of the ' water-soluble hydrophilic substance, the concentration of the hydrogel-forming polymer constituting the hydrogel may be increased. Further, the diffusion of the water-soluble hydrophilic substance also is dependent on the molecular weight of the substance. When the concentration of the hydrogel-forming polymer constituting the hydrogel is constant, as the molecular weight of a substance is increased, the diffusion - rate thereof becomes lower.
- the diffusion of a water-soluble hydrophobic substance in the hydrogel according to the present invention is influenced not only by the molecular sieving effect of the three-dimensional network structure of the hydrogel-forming polymer, but also by the distribution or partition thereof with respect to the hydrophobic portion of the hydrogel-forming polymer.
- the diffusion of the water-soluble hydrophobic substance is also controlled by the ratio of the hydrophobic portion in the hydrogel-forming polymer, and therefore, the diffusion of the water-soluble hydrophobic substance is generally slower than that of the water-soluble hydrophilic substance.
- the diffusion coefficient of a solute in the hydrogel can be obtained by the "early-time" approximation described in a publication , (Eric K. L. Lee et al, Journal of Membrane Science, 24, 125-143 (1985)).
- a process in which a solute uniformly diffused on a hydrogel flat plate having a uniform thickness of L (cm) is eluted from both of the surfaces of the hydrogel flat plate is observed along with the elapse of time.
- the diffusion coefficient D can be calculated from the gradient of a straight line obtained by plotting the elution rate to the elapsed time t versus the square root of the elapsed time t.
- the ratio of diffusion coefficients of phenol red (PR), methyl blue (MB) and myoglobin (MG) may preferably be such that (D PR /D MB ) > 2 and
- collagen as the conventional cell or tissue-culturing carrier, is a hydrophilic polymer. Unlike in the case of the hydrogel according to the present invention, a balance of hydrophilicity/hydrophobicity in collagen cannot be arbitrarily controlled. Accordingly, it has been difficult to control the diffusion rate of a chemical mediator in collagen.
- the hydrogel according to the present invention can substantially arbitrarily control a balance of hydrophilicity/hydrophobicity as stated above, it is possible to control the diffusion rate of a chemical mediator in the gel according to the present invention so as to provide a considerable degree of freedom.
- a known gel-forming polymer such as collagen
- a cell or tissue is used in the present invention to mean tissues, apparatuses or organs which are present in the living bodies of animals (especially humans).
- the in vivo tissue or organ which can be regenerated by using the carrier according to the present invention is not particularly limited. Examples of such tissue or organ may include: esophagus, stomach, small intestine, large intestine, pancreas, liver, heart, blood vessel, bone, cartilage, nerve, cornea, corium, etc. (Cell or tissue)
- the cells or tissue which can be cultured by using culturing carrier according to the present invention is not particularly limited.
- the culturing carrier according to the present invention can be used particularly effectively for differential cells or tissues.
- differential cells may include stem cells and precursor cells.
- the differential cells include any of differential unipotent cells, differential pluripotent cells, and differential totipotent cells. (Method of repairing or regenerating living organism tissue or organ)
- the method of repairing or regenerating a cell or tissue using the carrier according to the present invention is not particularly limited. From the viewpoint of easy inoculation and recovery of cells or the like, it is preferable to utilize the sol-gel transition of a hydrogel-forming polymer. (Embodiment of using sol-gel transition)
- a cell e.g., a stem cell or precursor cell
- tissue containing the cell, or the like is first inoculated or mixed into the earner according to the present invention.
- a hydrogel-forming polymer constituting the carrier used for culturing a cell or tissue of the present invention is dissolved in a culture medium such as RPMI- 1640 (Life Technologies, N.
- a culture medium used herein is not particularly limited.
- a culture medium in which a cell of interest (a stem cell, a precursor cell, etc.) easily grows or differentiates may be appropriately selected and used.
- the above described chemical mediator promoting the growth or differentiation of a stem cell or precursor cell of interest may also be added to such a culture medium, as desired.
- ECM such as collagen or gelatin may also be added thereto.
- tissue or organ in the carrier according to the present invention for example, the above suspension is heated to a temperature (usually 37 0 C) higher than the sol-gel transition temperature of the carrier according " to the present invention, so that it is gelatinized. Thereafter, " a cell of interest or tissue containing the cell may be cultured at the temperature (usually 37°C).
- the carrier according to the present invention When the carrier according to the present invention is gelatinized, it is also possible to gelatinize it in a desired form, using a mold having the desired form.
- a cartilage tissue when used in repair of the ear or nose, the carrier according to the present invention is converted into a form compatible with a portion of the ear or nose to which the cartilage tissue is to be applied. Thereafter, cartilage cells are cultured in the carrier according to the present invention, so as to regenerate a cartilage tissue.
- the cartilage tissue to be applied can be easily molded into a desired form and used.
- the carrier according to the present invention containing the tissue or organ of interest is cooled to a temperature (for example, 4 0 C) lower than the sol-gel transition temperature, so that the carrier according to the present invention is returned to a sol state.
- the tissue or organ of interest may be separated from the carrier according to the present invention by a common separation method such as centrifugal separation.
- the carrier according to the present invention substantially not to inhibit (or substantially to promote) the growth or differentiation of a cell of interest (a stem cell, a precursor cell, etc.), while controlling the growth of fibroblasts. Accordingly, a cell or organ of interest can be efficiently regenerated in the carrier according to the present invention.
- the solvent was distilled off under reduced pressure, the resultant residue was dissolved in distilled water, and subjected to ultrafiltration by using an ultrafiltration membrane having a molecular cutoff of 3 x 10 4 (Amicon PM-30) so as to fractionate the product into a low-molecular weight polymer fraction and a high-molecular weight polymer fraction.
- the resultant aqueous solution was frozen, to thereby obtain a high-polymerization degree product of F-127 and a low-polymerization degree product of F-127.
- This polymer was dissolved in distilled water under cooling with ice so as to provide a concentration of 5 mass %.
- sol-gel transition temperature of the resultant aqueous solution was measured, it was found that the sol-gel transition temperature was about 16 0 C.
- N-aclyloxy succinimide (mfd. by Kokusan Kagaku K.K.), and 7 g of n-butyl methacrylate (mfd.. by Kanto Kagaku K.K.) were dissolved in 4000 ml of chloroform. After the purging with nitrogen gas, 1.5 g of N,N'-azobisisobutyronitrile was added thereto, and the resultant mixture was subjected to polymerization at 60 0 C for 6 hours. The reaction mixture was concentrated, and then was reprecipitated in diethyl ether.
- poly(N-isopropyl acrylamide-co-N-aclyloxy succinimide-co-n-butyl methacrylate) was added to the thus obtained poly(N-isopropyl acrylamide-co-N-aclyloxy succinimide-co-n-butyl methacrylate) to thereby obtain poly(N-isopropyl acrylamide-co-n-butyl methacrylate).
- the thus obtained poly(N-isopropyl acrylamide-co-n-butyl methacrylate) had a sol-gel transition o temperature of about 19 °C in its aqueous solution.
- This polymer was dissolved in distilled water under cooling with ice so as to provide a concentration of 5 mass %.
- sol-gel transition temperature of the resultant aqueous solution was measured, it was found that the sol-gel transition temperature was about 21 0 C.
- TGP-I ethylene oxide gas
- EOG ethylene oxide gas
- Hybrid Sterilization bag mfd. by Hogi Medical Co.
- EOG sterilizing device trade name: Easy Pack, mfd. Inouchi Seieido Co.
- the bag was placed in a vacuum drying chamber (40 0 C) and was left standing for half ' a day, and was sterilized while the bag was sometimes subjected to aeration.
- the concentrated solution was diluted with 4 L of distilled water, and then, the dilution operation was carried out again.
- the above dilution and concentration by ultrafiltration were further repeated 5 times, so as to eliminate products having a molecular weight of 10 x 10 4 or lower.
- the product which had not been filtrated by this ultrafiltration i.e., the product remaining in the inside of the ultrafiltration membrane
- TGP -4 (TGP -4) according to the present invention having a molecular weight of 10 x 10 4 or higher.
- the hydrogel-forming polymer (TGP -3) according to the present invention which had been obtained in Production Example 3 was dissolved so as to provide a concentration of 10 mass % in distilled water.
- the steady flow viscosity ⁇ thereof at 37°C was measured, it was found to be 5.8 x 10 5 Pa sec.
- a stress rheometer (CSL 500), and an acryl disk (diameter: 4 cm) as a measuring device were used.
- the thickness of a sample was set to 600 ⁇ m, and applying a shearing stress of 10 N/m 2 , the resultant creep was measured for 5 minutes after 5 minutes had passed.
- Production Example 8 42.0 g of N-isopropylacrylamide and 4.0 g of n-butyl methacrylate were dissolved in 592 g of ethanol. To the resultant mixture solution, an aqueous solution which had been obtained by dissolving 11.5 g of polyethylene glycol dimethacrylate (PDE 6000, mfd. by NOF Corporation) in 65.1 g of water was added. The resultant solution was heated to 70 0 C under a nitrogen stream.
- PDE 6000 polyethylene glycol dimethacrylate
- the solution was concentrated to 2 L at 5 0 C, by using an ultrafiltration membrane with a molecular weight cutoff of 10x 10 4 .
- 4 L of cold distilled water was added to the concentrated solution for dilution, and the above concentration operation using the ultrafiltration was conducted again. Thereafter, the above dilution and ultrafiltration concentration were repeated 5 times, so as to eliminate The product with a molecular weight of 10x 10 or lower.
- the product which had not been filtrated by the above ultrafiltration (product remaining in the ultrafiltration membrane) was recovered and freeze-dried, so as to obtain 40 g of the hydrogel-forming polymer (TGP-6) according to the present invention with a molecular weight of 10x 10 4 or higher.
- TGP-5 1 g was dissolved in 10 mL of Dulbecco's Minimum Essential Medium (DMEM) containing 20% Fetal Bovine Serum (FBS) at 4 0 C. Corneal Limbal tissue bits " of about 2 mm 3 were collected from donor A, and the corneal limbal tissue bits of about 2 mm 3 obtained were further cut into smaller pieces (1 mm 3 or less).
- DMEM Dulbecco's Minimum Essential Medium
- FBS Fetal Bovine Serum
- Corneal Limbal tissue bits " of about 2 mm 3 were collected from donor A, and the corneal limbal tissue bits of about 2 mm 3 obtained were further cut into smaller pieces (1 mm 3 or less).
- 0.2 mL of TGP-5 solution in DMEM cooled to 4°C was placed in the center of the wells of a 24-well plate warmed to 37 0 C and converted into a gel state.
- the above corneal limbal tissue bits of about 1 mm 3 or less were placed on top of this, and a few drops of TGP-5 solution in DMEM cooled to 4 0 C were further added. This was kept in cultivation at 37°C, after which corneal limbal tissue bits were embedded within the TGP-5 gel.
- 0.5 mL of DMEM (containing 20% FBS) medium at 37°C was added on top of the gel, and incubated under 10% CO 2 atmosphere at 37°C.
- the layered medium on top of the gel (0.5 mL) was exchanged every 3 days with 0.5 mL of fresh DMEM (containing 20% FBS) medium.
- TGP-5 1 g of TGP-5 was dissolved in 10 mL of DMEM (containing 20% FBS) medium at 4°C.
- Corneal Limbal tissue bits of about 2 rah 3 were collected from donor B (male, 8 years old), and the corneal limbal tissue bits of about 2 mm 3 obtained were further cut into smaller pieces (1 mm 3 or less).
- 0.2 mL of TGP-5 solution in DMEM cooled to 4°C was placed in the center of the wells of a 24-well plate warmed to 37°C and converted into a gel state. The above corneal limbal tissue bits of about 1 mm 3 or less were placed on top of this, and a few drops of TGP-5 solution in DMEM cooled to 4°C were further added.
- Tissue after 5 days of cultivation was fixed with formalin and stained with hematoxylin eosin (HE) ( Figure 5), thereby showing grown cellular layer around the tissue bits.
- Paraffin embedded sections 4-5 mm thick were prepared from the above tissue bits after 5 days of cultivation, and peroxidase immunostaining by various markers was performed.
- Anti-human p63 (4A4) mouse antibody (DAKO), anti-human ABCG2 (5D3) mouse antibody (DAKO), anti-human connexin 43 mouse antibody (DAKO), and anti-human integrin ⁇ 4 (A9) mouse antibody (DAKO) were used as primary antibodies.
- the grown cellular population contained cells which are positive for p63 specific to corneal limbal stem cells and connexin 43 specific to transient growing cells, and cells which are positive for ABCG2 specific to corneal limbal stem cells having pluripotency and integrin ⁇ specific to mature corneal epithelial cells were not observed.
- ABCG2 cells which are positive in immunoperoxidase staining on day 11 of cultivation were observed.
- human amniotic membrane tissue obtained by Caeserian section was washed, and then trypsinized for 45 minutes to remove epithelial cells.
- the human amniotic membrane tissue with epithelial cells removed were placed in a 24-well plate, and the corneal limbal tissue bits of about 1 mm 3 or less obtained from donor B (male, 8 years old) in Example 2 were placed on top of this.
- 0.5 mL of DMEM (containing 20% FBS) medium was added and this was cultivated under 10% CO 2 atmosphere at 37 0 C. The medium was exchanged every 3 days with 0.5 mL of fresh DMEM (containing 20% FBS) medium.
- Example 2 Tissue after 5 days of cultivation was fixed with formalin, paraffin embedded sections 4-5 mm thick were prepared, and peroxidase immunostaining by various markers similar to Example 2 was performed. As a result, the grown cells were negative to all of p63, connexin 43, ABCG2, and mxegrin ⁇ . Comparative Example 2 (cultivation only on a plate)
- Corneal limbal tissue bits of about 1 mm 3 or less obtained from donor B (male, 8 years old) in Example 2 were placed directly on the bottom of a 24-well plate.
- 0.5 mL of DMEM (containing 20% FBS) medium was added and this was cultivated under 10% CO 2 atmosphere at 37°C.
- the medium was exchanged every 3 days with 0.5 mL of fresh DMEM (containing 20% FBS) medium.
- Tissue after 5 days of cultivation was fixed with formalin and stained with hematoxylin eosin (HE), thereby showing that tissue bits had disintegrated and no grown cells were observed around the perimeter.
- HE hematoxylin eosin
- TGP-5 1 g of TGP-5 was dissolved in 10 mL of DMEM (containing 20% FBS) medium at 4°C.
- Corneal limbal tissue bits of about 2 mm 3 were collected from donor C (male, 85 years old), and the corneal limbal tissue bits of about 2 mm 3 obtained were further cut into smaller pieces (1 mm 3 or less).
- 0.2 mL of TGP:5 solution in DMEM cooled to 4 0 C was placed in the center, of the wells of a 24-well plate warmed to 37°C and converted into a gel state. The above corneal limbal tissue bits of about 1 mm 3 or less were placed on top of this, and a few drops of TGP-5 solution in DMEM cooled to 4 0 C were further added.
- the grown cellular population was negative for p63 specific to corneal limbal stem cells, but contained cells which were positive for connexin 43 specific to transient growing cells, ABCG2 specific to corneal limbal stem cells having pluripotency, and inlegrin ⁇ specific to mature corneal epithelial cells.
- Figure: 10 Comparative Example 2 (cultivation using amniotic membrane)
- human amniotic membrane tissue obtained by Caeserian section was washed, and then trypsinized for 45 minutes to remove epithelial cells.
- the human amniotic membrane tissue with epithelial cells removed were placed in a 24-well plate, and the corneal limbal tissue bits of about 1 mm 3 or less obtained from donor C (male, 85 years old) in Example 3 were placed on top of this.
- 0.5 mL of DMEM (containing 20% FBS) medium was added and this was cultivated under
- Example 4 I g of TGP-5 was dissolved in 10 mL of DMEM (containing 20% FBS) medium at 4 0 C. Corneal limbal tissue bits of about 2 mm 3 were collected from donor D (female, 65 years old), and the corneal limbal tissue bits of about 2 mm obtained were further cut into smaller pieces (1 mm 3 or less). 0.2 mL of TGP-5 solution in DMEM cooled to 4 0 C was placed in the center of the wells of a 24-well plate warmed to 37°C and converted into a gel state. The above corneal limbal tissue bits of about 1 mm 3 or less were placed on top of this, and a few drops of TGP-5 solution in DMEM cooled to 4 0 C were further added.
- DMEM containing 20% FBS
- the grown cellular population was negative for ABCG2 specific to corneal limbal stem cells having pluripotency, but contained cells which were positive for p63 specific to corneal limbal stem cells, connexin 43 specific to transient growing cells, and integrin ⁇ specific to mature corneal epithelial cells. (Figure: 1 1)
- Example 5 1 g of TGP-5 was dissolved in 10 mL of DMEM (containing 20% FBS) medium at 4°C. Corneal limbal tissue bits of about 2 mm 3 were collected from donor E (male, 76 years old), and the corneal limbal tissue bits of about 2 mm 3 obtained were further cut into smaller pieces (1 mm 3 or less). 0.2 mL of TGP-5 solution in DMEM cooled to 4 0 C was placed in the center of the wells of a 24-well plate warmed to 37 0 C and converted into a gel state. The above corneal limbal tissue bits of about 1 mm 3 or less were placed on top of this, and a few drops of TGP-5 solution in DMEM cooled to 4 0 C were further added.
- DMEM containing 20% FBS
- Example 6 1 g of TGP-5 was dissolved in 10 mL of DMEM (containing 20% FBS) medium at 4°C. Corneal limbal tissue bits of about 2 mm 3 were collected from donor F (male, 32 years old), and the corneal limbal tissue bits of about 2 mm 3 obtained were further cut into smaller pieces (1 mm 3 or less). 0.2 mL of TGP-5 solution in DMEM cooled to 4 0 C was placed in the center of the wells of a 24-well plate warmed to 37 0 C and converted into a gel state. The above corneal limbal tissue bits of about 1 mm 3 or less were placed on top of this, and a few drops of TGP-5 solution in DMEM cooled to 4 0 C were further added.
- DMEM containing 20% FBS
- Tissue after 10 days of cultivation was fixed with formalin and paraffin embedded sections 4-5 mm thick were prepared, and peroxidase immunostaining by various markers, was performed.
- the grown cellular population were negative for ABCG2 specific to corneal limbal stem cells having pluripotency, but contained cells which were positive for p63 specific to corneal limbal stem cells, connexin 43 specific to transient growing cells, and integrin ⁇ specific to mature corneal epithelial cells.
- Example 7 I g of TGP-5 was dissolved in 10 mL of DMEM (containing 20% FBS) medium at 4°C.
- Cadaveric Corneal limbal tissue bits of about 2 mm 3 were collected from donor G (female, 78 years old), and the corneal limbal tissue bits of about 2 mm 3 obtained were further cut into smaller pieces (1 mm 3 or less).
- 0.2 mL of TGP-5 solution in DMEM cooled to 4 0 C was placed in the center of the wells of a 24-well plate warmed to 37°C and converted into a gel state. The above corneal limbal tissue bits of about 1 mm 3 or less were placed on top of this, and a few drops of TGP-5 solution in DMEM cooled to 4 0 C were further added.
- Tissue after 13 days of cultivation was fixed with formalin and paraffin embedded sections 4-5 mm thick were prepared, and peroxidase immunostaining by various markers was performed.
- the grown cellular population contained -cells which were positive for p63 specific to corneal limbal stem cells.
- TGP-5 1 g of TGP-5 was dissolved in 10 mL of DMEM (containing 20% FBS) medium at 4 0 C.
- Corneal limbal tissue bits of about 2 mm 3 were collected from donor H (male, 68 years old), and the corneal limbal tissue bits of about 2 mm 3 obtained were further cut into smaller pieces (1 mm 3 or less).
- 0.2 mL of TGP-5 solution in DMEM cooled to 4°C was placed in the center of the wells of a 24-well plate warmed to 37°C and converted into a gel state. The above corneal limbal tissue bits of about 1 mm 3 or less were placed on top of this, and a few drops of TGP-5 solution in DMEM cooled to 4 0 C were further added.
- Tissue after 10 days of cultivation was fixed with formalin and paraffin embedded sections 4-5 mm thick were prepared, and peroxidase immunostaining by various markers was performed.
- the grown cellular population contained cells, which were positive for p63 specific to corneal limbal stem cells.
- Example 9 I g of TGP-5 was dissolved in 10 mL of DMEM (containing 20% FBS) medium at 4 0 C. Corneal limbal tissue bits of about 2 mm 3 were collected from donor I (male, 62 years old), and the corneal limbal tissue bits of about 2 mm 3 obtained were further cut into smaller pieces (1 mm 3 or less). 0.2 mL of TGP-5 solution in DMEM cooled to 4 0 C was placed in the center of the wells of a 24* well plate warmed to 37°C and converted into a gel state. The. above corneal limbal tissue bits of about 1 mm 3 or less were placed on top of this, and a few drops of TGP-5 solution in DMEM cooled to 4°C were further added. This was kept in cultivation at 37 0 C, after which corneal limbal tissue bits were embedded within the TGP-5 gel. 0.5 mL of DMEM (containing 20% FBS) medium at
- TGP-5 1 g of TGP-5 was dissolved in 10 mL of DMEM (containing 20% FBS) medium at 4 0 C.
- Corneal limbal tissue bits of about 2 mm 3 were collected from donor J (male, 79 years old), and the corneal limbal tissue bits of about 2 mm 3 obtained were further cut into smaller pieces (1 mm 3 or less).
- 0.2 mL of TGP-5 solution in DMEM cooled to 4°C was placed in the center of the wells of a 24-well plate warmed to 37°C and converted into a gel state. The above corneal limbal tissue bits of about 1 mm 3 or less were placed on top of this, and a few drops of TGP-5 solution in DMEM cooled to 4 0 C were added.
- Example 10 With a sample from donor J (male " , 79 years old) in Example 10, experiments similar to Example 10 (cultivation according to the present invention), Comparative Example 1 (cultivation on amniotic membrane tissue), and Comparative Example 2 (cultivation on a plate) were performed using DMEM medium containing 1 ⁇ Ci per well of tritium ⁇ -labelled thymidine. 50 ⁇ L per well of medium was sampled every day, the amount of radiation was measured with a scintillation counter, and the reduction of thymidine incorporated by the cell for DNA synthesis was compared, to obtain an indicator for cell growth activity.
- TGP-5 1 g of TGP-5 was dissolved in 10 mL of DMEM (containing 20% FBS) medium at 4 0 C.
- Cadaveric Corneal limbal tissue bits of about 2 mm 3 were collected from donor K (male, 98 years old), and the corneal limbal tissue bits of about 2 mm 3 obtained were further cut into smaller pieces (1 mm 3 or less).
- 0.2 mL of TGP-5 solution in DMEM cooled to 4 0 C was placed in the center of the wells of a 24-well plate warmed to 37 0 C and converted into a gel state. The above corneal limbal tissue bits of about 1 mm or less were placed on top of this, and a few drops of TGP-5 solution in DMEM cooled to 4°C were added.
- Example 13 With a sample from donor K (male, 98 years old) in Example 12, experiments similar to Example 12 (cultivation according to the present invention), Comparative Example 1 (cultivation on amniotic membrane tissue), and Comparative Example 2 (cultivation on a plate) were performed using DMEM medium containing 1 ⁇ Ci per well of tritium 3 H-labelled thymidine. 50 ⁇ L per well of medium was sampled every day, the amount of radiation was measured with a scintillation counter, and the reduction of thymidine incorporated by the cell for DNA synthesis was compared, to obtain an indicator for cell growth activity.
- TGP-5 1 g of TGP-5 was dissolved in 10 mL of DMEM (containing 20% FBS) medium at 4°C.
- Cadaveric Corneal limbal tissue bits of about 2 mm 3 were collected from donor L (female, 56 years old), and the corneal limbal tissue bits of about 2 mm 3 obtained were further cut into smaller pieces (1 mm 3 or less).
- 0.2 mL of TGP-5 solution in DMEM cooled to 4 0 C was placed in the center of the wells of a 24-well plate warmed to 37 0 C and converted into a gel state. The above corneal limbal tissue bits of about 1 mm 3 or less were placed on top of this, and a few drops of TGP-5 solution in DMEM cooled to 4°C were added.
- PBS PBS
- the cellular population collected contained p63 positive cells specific to corneal limbal stem cells, ABCG2 positive cells specific to corneal limbal stem cells having pluripotency, connexin 43 positive cells specific to transient growing cells, and integrin ⁇ positive cells specific to mature corneal epithelial cells positive.
- cellular population from corneal limbus can be obtained according to the present invention, even when corneal limbal stem cells and corneal epithelial cells, which they differentiate into, cannot be obtained by cultivating corneal limbal tissue on amniotic membrane tissue or on typical cell cultivation plates.
- collecting of only, the cells from corneal limbal tissue are done with ease, and the cells can be provided for various treatments for diseases associated with cornea.
- the cellular population from corneal limbus obtained from the present invention can be stored frozen according to usual methods, to be thawed and used when a patient is in need thereof.
- the cells derived from corneal limbal tissue obtainable from the present invention it is possible to fix only the relevant cells onto the cornea of a patient using for example therapeutic contact lens. There is no need to transplant the cells together with human amniotic membrane tissue as with conventional methods.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Neurosurgery (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Neurology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Ophthalmology & Optometry (AREA)
- Developmental Biology & Embryology (AREA)
- Materials For Medical Uses (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/IN2005/000092 WO2006103685A2 (en) | 2005-03-28 | 2005-03-28 | A method for cultivating cells derived from corneal limbal tissue and cells deived from corneal limbal tissue |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/IN2005/000092 WO2006103685A2 (en) | 2005-03-28 | 2005-03-28 | A method for cultivating cells derived from corneal limbal tissue and cells deived from corneal limbal tissue |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2006103685A2 true WO2006103685A2 (en) | 2006-10-05 |
WO2006103685A3 WO2006103685A3 (en) | 2006-12-21 |
Family
ID=37053797
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IN2005/000092 WO2006103685A2 (en) | 2005-03-28 | 2005-03-28 | A method for cultivating cells derived from corneal limbal tissue and cells deived from corneal limbal tissue |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2006103685A2 (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2016510727A (en) * | 2013-02-19 | 2016-04-11 | チルドレンズ メディカル センター コーポレーション | ABCB5 (+) stem cells for treating eye diseases |
US9561264B2 (en) | 2000-06-05 | 2017-02-07 | The Brigham And Women's Hospital, Inc. | Gene encoding a multidrug resistance human P-glycoprotein homologue on chromosome 7p15-21 and uses thereof |
CN106591216A (en) * | 2016-12-12 | 2017-04-26 | 深圳市眼科医院 | Human normal corneal epithelium cells and application thereof |
WO2017158505A1 (en) * | 2016-03-15 | 2017-09-21 | Mebiol Inc. | Enhancing the function immunocytes and hemocytes using tgp and microgravity |
US10017738B2 (en) | 2006-05-31 | 2018-07-10 | Children's Medical Center Corporation | ABCB5 positive mesenchymal stem cells as immunomodulators |
US10655120B2 (en) | 2011-03-21 | 2020-05-19 | The University Of Newcastle Upon Tyne | Transport of cells in hydrogels |
RU2809076C1 (en) * | 2023-07-14 | 2023-12-06 | Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт глазных болезней им. М.М. Краснова" (ФГБНУ "НИИ глазных болезней им. М.М. Краснова") | Method of obtaining limbal stem cells in collagen hydrogel |
-
2005
- 2005-03-28 WO PCT/IN2005/000092 patent/WO2006103685A2/en not_active Application Discontinuation
Non-Patent Citations (5)
Title |
---|
CHEN Z. ET AL.: 'Characterization of Putative Stem Cell Phenotype in Human Limbal Epithelia' STEM CELLS vol. 22, 2004, pages 355 - 366, XP003007062 * |
LI D.-Q. ET AL.: 'Partial Enrichment of a Population of Human Limbal Epithelial Cells with Putative Stem Cell Properties Based on Collagen Type IV Adhesiveness' EXPERIMENTAL EYE RESEARCH vol. 80, 2005, pages 581 - 590, XP004801658 * |
MADHAVAN H.N. ET AL.: 'A Study on the Growth of Continuous Culture Cell Lines Embedded in Mebiol Gel' CURRENT SCIENCE vol. 87, no. 9, 10 November 2004, pages 1275 - 1277, XP003007063 * |
SEIGEL G.M. ET AL.: 'Human Corneal Stem Cells Display Functional Neuronal Properties' MOLECULAR VISION vol. 9, 2003, pages 159 - 163, XP003007061 * |
WATANABE K. ET AL.: 'Human Limbal Epithelium Contains Side Population Cells Expressing the ATP-Binding Cassette Transporter ABCG2' FEBS LETTERS vol. 565, 2004, pages 6 - 10, XP004507669 * |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9561264B2 (en) | 2000-06-05 | 2017-02-07 | The Brigham And Women's Hospital, Inc. | Gene encoding a multidrug resistance human P-glycoprotein homologue on chromosome 7p15-21 and uses thereof |
US10017738B2 (en) | 2006-05-31 | 2018-07-10 | Children's Medical Center Corporation | ABCB5 positive mesenchymal stem cells as immunomodulators |
US11624054B2 (en) | 2006-05-31 | 2023-04-11 | The Brigham And Women's Hospital, Inc. | ABCB5 positive mesenchymal stem cells as immunomodulators |
US10655120B2 (en) | 2011-03-21 | 2020-05-19 | The University Of Newcastle Upon Tyne | Transport of cells in hydrogels |
EP3865573A1 (en) * | 2013-02-19 | 2021-08-18 | Children's Medical Center Corporation | Abcb5(+) stem cells for treating ocular disease |
US9801912B2 (en) | 2013-02-19 | 2017-10-31 | Va Boston Healthcare System | ABCB5(+) stem cells for treating ocular disease |
JP2019189600A (en) * | 2013-02-19 | 2019-10-31 | ザ チルドレンズ メディカル センター コーポレーション | Abcb5(+) stem cells for treating ocular disease |
JP2016510727A (en) * | 2013-02-19 | 2016-04-11 | チルドレンズ メディカル センター コーポレーション | ABCB5 (+) stem cells for treating eye diseases |
US11129854B2 (en) | 2013-02-19 | 2021-09-28 | Schepens Eye Research Institute | ABCB5(+) stem cells for treating ocular disease |
EP2964238A4 (en) * | 2013-02-19 | 2016-09-07 | Childrens Medical Center | ABCB5 (+) STEM CELLS USEFUL FOR THE TREATMENT OF OCULAR DISEASE |
WO2017158505A1 (en) * | 2016-03-15 | 2017-09-21 | Mebiol Inc. | Enhancing the function immunocytes and hemocytes using tgp and microgravity |
CN106591216A (en) * | 2016-12-12 | 2017-04-26 | 深圳市眼科医院 | Human normal corneal epithelium cells and application thereof |
RU2809076C1 (en) * | 2023-07-14 | 2023-12-06 | Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт глазных болезней им. М.М. Краснова" (ФГБНУ "НИИ глазных болезней им. М.М. Краснова") | Method of obtaining limbal stem cells in collagen hydrogel |
Also Published As
Publication number | Publication date |
---|---|
WO2006103685A3 (en) | 2006-12-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6897064B2 (en) | Cell or tissue-culturing carrier, and culturing method | |
US20030104347A1 (en) | Coating material for living organism tissue, coated product from living organism tissue and method of coating living organism material | |
Uludag et al. | Technology of mammalian cell encapsulation | |
KR101053792B1 (en) | Biosynthetic Matrix and Uses thereof | |
US10052350B2 (en) | Fabrication of gelatin hydrogel sheet for the transplantation of corneal endothelium | |
EP1407791A1 (en) | Material for tissue/organ regeneration and method of tissue/organ regeneration | |
Kim et al. | Engineering retinal pigment epithelial cells regeneration for transplantation in regenerative medicine using PEG/Gellan gum hydrogels | |
EP2266499A2 (en) | Three-dimensional tissue structure | |
Rao et al. | Implantable controlled delivery systems for proteins based on collagen—pHEMA hydrogels | |
US20120071580A1 (en) | Suturable Hybrid Superporous Hydrogel Keratoprosthesis for Cornea | |
US20080112995A1 (en) | Implantable Bioreactors and Uses Thereof | |
TWI673103B (en) | Injectable self-assembling microbead-gel, use thereof, and method for preparing injectable self-assembling microbead-gel | |
US20100080840A1 (en) | Hybrid superporous hydrogel scaffold for cornea regeneration | |
US20160144069A1 (en) | Suturable hybrid superporous hydrogel keratoprosthesis for cornea | |
JP2004501700A (en) | Biocompatible polymer having three-dimensional structure using communicating cells, method for preparing the same, and application in medicine and surgery | |
CN116948411A (en) | Superelastic hydrogel material, superelastic injectable stent and preparation method and application thereof | |
WO2006103685A2 (en) | A method for cultivating cells derived from corneal limbal tissue and cells deived from corneal limbal tissue | |
Sipehia et al. | Towards an artificial cornea: surface modifications of optically clear, oxygen permeable soft contact lens materials by ammonia plasma modification technique for the enhanced attachment and growth of corneal epithelial cells | |
EP4499160B1 (en) | Use of polymer-based microcarriers in the production of tissue scaffolds with complex geometry | |
CN106421925B (en) | Preparation method based on glycosaminoglycan bionic extracellular matrix hydrogel as pancreas islet culture bracket | |
JP2004043749A (en) | Hydrogel, gelatinous material and method for controlling diffusion of substance | |
CN116075326A (en) | Multi-layered cell capsules and uses thereof | |
US20230355844A1 (en) | Electrospun Reinforced Suturable Artificial Cornea and Uses Thereof | |
JP6264765B2 (en) | Tissue preparation method |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 4226/CHENP/2007 Country of ref document: IN |
|
NENP | Non-entry into the national phase in: |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: DE |
|
NENP | Non-entry into the national phase in: |
Ref country code: RU |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: RU |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 05733277 Country of ref document: EP Kind code of ref document: A2 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 5733277 Country of ref document: EP |